The Pulse of New York Tech
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders. Founded in 2018, Hemab is backed by investors that include Novo Holdings and is headquartered in Copenhagen.
WRITE FOR US
NYC TECH EVENTS
NYC TECH NEWS
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.